Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.
Herrlinger KR, Witthoeft T, Raedler A, Bokemeyer B, Krummenerl T, Schulzke JD, Boerner N, Kueppers B, Emmrich J, Mescheder A, Schwertschlag U, Shapiro M, Stange EF. Herrlinger KR, et al. Among authors: bokemeyer b. Am J Gastroenterol. 2006 Apr;101(4):793-7. doi: 10.1111/j.1572-0241.2005.00356.x. Am J Gastroenterol. 2006. PMID: 16635225 Clinical Trial.
Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study.
Plachta-Danielzik S, Grasskemper L, Schmidt K, Schreiber S, Bokemeyer B. Plachta-Danielzik S, et al. Among authors: bokemeyer b. JMIR Res Protoc. 2023 May 8;12:e42574. doi: 10.2196/42574. JMIR Res Protoc. 2023. PMID: 37155235 Free PMC article.
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
Bokemeyer B, Hlavaty T, Allez M, Selema P, Moosavi S, Cadatal MJ, Fowler H, Mueller M, Liau KF, Gisbert JP. Bokemeyer B, et al. Expert Opin Biol Ther. 2023 Jul-Dec;23(8):791-800. doi: 10.1080/14712598.2023.2200883. Epub 2023 Apr 16. Expert Opin Biol Ther. 2023. PMID: 37038897 Free article.
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, Hoffstadt M, Ehehalt R, Trentmann L, Schweitzer A, Jessen P, Hartmann P, Schreiber S. Bokemeyer B, et al. Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. doi: 10.1111/apt.17616. Epub 2023 Jun 15. Aliment Pharmacol Ther. 2023. PMID: 37322825
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Dignass AU, Bokemeyer B, Adamek H, Mross M, Vinter-Jensen L, Börner N, Silvennoinen J, Tan G, Pool MO, Stijnen T, Dietel P, Klugmann T, Vermeire S, Bhatt A, Veerman H. Dignass AU, et al. Among authors: bokemeyer b. Clin Gastroenterol Hepatol. 2009 Jul;7(7):762-9. doi: 10.1016/j.cgh.2009.04.004. Epub 2009 Apr 16. Clin Gastroenterol Hepatol. 2009. PMID: 19375519 Clinical Trial.
131 results